Allogeneic stem-cell transplantation provides excellent in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy

Leukemia and Lymphoma

Volumn 48, Issue 2, 2007, Pages 295-301

  Weisser, Martin ^a,b   Schleuning, Michael ^c   Haferlach, Claudia ^d   Schwerdtfeger, Rainer ^c   Kolb, Hans Jochem ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^d Munich Leukaemia Laboratory   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; HYDROXYUREA; IMATINIB; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CELL NUCLEUS; CHRONIC DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTERPHASE; LEUKEMIA RELAPSE; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; QUALITATIVE ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; ALLOTRANSPLANTATION; DRUG ANTAGONISM; GENETICS; GRAFT VERSUS LEUKEMIA EFFECT; INCIDENCE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REMISSION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; FUSION PROTEINS, BCR-ABL; GRAFT VS LEUKEMIA EFFECT; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 34247877678     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601078464     Document Type: Article

References (24)

1. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F. and Ford, J. M. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med, 344, pp. 1038-1042.
2. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E. and Ford, J. M. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344, pp. 1031-1037.
3. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M. and Cervantes, F. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 348, pp. 994-1004.
4. Sawyers, C. L., Hochhaus, A., Feldman, E., Goldman, J. M., Miller, C. B. and Ottmann, O. G. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood, 99, pp. 3530-3539.
5. Talpaz, M., Silver, R. T., Druker, B. J., Goldman, J. M., Gambacorti-Passerini, C. and Guilhot, F. (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood, 99, pp. 1928-1937.
6. Hehlmann, R., Hochhaus, A., Kolb, H. J., Hasford, J., Gratwohl, A. and Heimpel, H. (1999) Interferon-α before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood, 94, pp. 3668-3677.
7. Gratwohl, A., Hermans, J., Goldman, J. M., Arcese, W., Carreras, E., Devergie, A. and for Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet, 352, pp. 1087-1092.
8. Bornhauser, M., Kroger, N., Schwerdtfeger, R., Schafer-Eckart, K., Sayer, H. G., Scheid, C. and for the Cooperative German Transplant Study Group (2006) Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: A retrospective multicentre study. Eur J Haematol, 76, pp. 9-17.
9. Visani, G., Rosti, G., Bandini, G., Tosi, P., Isidori, A. and Malagola, M. (2000) Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. Br J Haematol, 109, pp. 722-728.
10. Schoch, C., Schnittger, S., Bursch, S., Gerstner, D., Hochhaus, A. and Berger, U. (2002) Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: A study on 350 cases. Leukemia, 16, pp. 53-59.
11. Weisser, M., Schleuning, M., Ledderose, G., Rolf, B., Schnittger, S. and Schoch, C. (2004) Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant, 34, pp. 1083-1088.
12. Schmid, C., Schleuning, M., Ledderose, G., Tischer, J. and Kolb, H. J. (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol, 23, pp. 5675-5687.
13. Thomas, E. D., Storb, R., Clift, R. A., Fefer, A., Johnson, L. and Neiman, P. E. (1975) Bone-marrow transplantation (second of two parts). N Engl J Med, 292, pp. 895-902.
14. Deininger, M., Schleuning, M., Greinix, H., Sayer, H. G., Fischer, T., Martinez, J. and for the European Blood and Marrow Transplantation Group (2006) The effect of prior exposure to imatinib on transplant-related mortality. Haematologica, 91, pp. 452-459.
15. McGlave, P. B., Shu, X. O., Wen, W., Anasetti, C., Nademanee, A. and Champlin, R. (2000) Unrelated donor marrow transplantation for chronic myelogenous leukaemia: 9 years' experience of the National Marrow Donor Program. Blood, 95, pp. 2219-2225.
16. Gale, R. P., Hehlmann, R., Zhang, M. J., Hasford, J., Goldman, J. M., Heimpel, H. and Study Group (1998) Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood, 91, pp. 1810-1819.
17. Schaich, M., Schakel, K., Illmer, T., Ehninger, G. and Bornhauser, M. (2003) Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation. Ann Hematol, 82, pp. 303-304.
18. Kim, D. W., Chung, Y. J., Lee, S., Kim, Y. J., Chung, N. G. and Kim, J. A. (2004) Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia. Leukemia, 18, pp. 1907-1909.
19. Koch, M., Lang, P., Bader, P., Kreyenberg, H., Schumm, M. and Scheel-Walter, H. (2003) Successful unrelated allogeneic stem cell transplantation after treatment of lymphoid blast crisis CML with imatinib and imatinib-containing conditioning regimen in a 16-year-old male. Bone Marrow Transplant, 32, pp. 541-542.
20. Staber, P. B., Brezinschek, R., Linkesch, W., Sill, H. and Neumeister, P. (2003) Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia. Haematologica, 88, p. ECR29.
21. Koh, L. P., Hwang, W. Y., Chuah, C. T., Linn, Y. C., Goh, Y. T. and Tan, C. H. (2003) Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis. Bone Marrow Transplant, 31, pp. 305-308.
22. Zander, A. R., Zabelina, T., Renges, H., Schider, H., Kratochwille, A. and Fehse, N. (2003) Pretreatment with Glivec increases transplant related mortality after allogeneic transplant. Blood, p. 102.
23. Shimoni, A., Kroger, N., Zander, A. R., Rowe, J. M., Hardan, I. and Avigdor, A. (2003) Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia, 17, pp. 290-297.
24. Wassmann, B., Pfeifer, H., Scheuring, U., Klein, S. A., Gokbuget, N. and Binckebanck, A. (2002) Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph ALL). Leukemia, 16, pp. 2358-2365.